Advancements in Diabetes Care: Monitoring, Cardiovascular Risk, and Personalized Management

Monthly Review: Journal of Diabetes Investigation (Vol.4, Issue 5)

Issue Summary (JDI Vol.4, Issue 5)

This issue of the Journal of Diabetes Investigation presents several key studies offering insights into improving diabetes management, predicting cardiovascular risks, and understanding the disease's varied impacts. Research highlights the benefit of structured self-monitoring for better long-term blood sugar control in insulin-treated patients. A notable study identifies serum adiponectin as a predictor for coronary heart disease risk in Japanese patients with type 2 diabetes, similar to Caucasians, suggesting a universal marker.

Furthermore, findings emphasize the importance of assessing visceral fat (fat around internal organs) over just body mass index (BMI) for effective weight-loss strategies to improve glycemic control, especially for those at risk of diabetes. The issue also delves into microvascular complications, revealing distinct cellular changes in the cornea (the clear front part of the eye) of type 2 diabetes patients, linked to disease duration and nerve damage.

Finally, a significant population study from Korea provides a snapshot of diabetes trends, showing increasing prevalence and improved control of blood pressure and lipids, though glycemic control (blood sugar levels) remains a challenge. These studies collectively underscore the ongoing efforts to enhance personalized care, refine risk assessment, and improve overall outcomes for individuals living with diabetes.

Disclaimer
The information presented in this article is provided for informational purposes only. The blog and its author assume no responsibility for the accuracy, safety, completeness, or reliability of the information. Any actions or decisions based on the information in this article are the sole responsibility of the reader.

This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.

Structured self‐monitoring of blood glucose reduces glycated hemoglobin in insulin‐treated diabetes

Research Objective
This study aimed to determine if structured self-monitoring of blood glucose (SMBG) could help improve blood sugar control in people with diabetes who are on insulin but whose blood sugar levels are not well-controlled.

Methods
Researchers assigned 86 insulin-treated patients to one of two groups: a routine testing group or a structured testing group. The structured group used a special chart to record their blood glucose levels seven times a day for three consecutive days each month. The main goal was to see changes in their HbA1c (a measure of average blood sugar over 2-3 months) after 3 and 6 months.

Main Findings
At 3 months, there was no significant difference in HbA1c between the groups. However, after 6 months, the structured testing group showed significantly better HbA1c levels compared to the routine testing group. Their HbA1c decreased by 0.5% (from 7.9% to 7.4%), while the routine group's HbA1c only decreased by 0.1% (from 7.9% to 7.8%). A majority (55%) of patients in the structured group were willing to continue this method, and they achieved an even greater HbA1c decrease of 0.7%.

Clinical Significance
These findings suggest that a structured approach to self-monitoring blood glucose can significantly improve long-term blood sugar control in people with insulin-treated diabetes.

Key Points for Patients
If you're managing diabetes with insulin, a more organized way of checking your blood sugar can be very helpful. Even a simple chart to record your levels a few days a month can lead to better overall blood sugar control over time. Consistent efforts can make a meaningful difference in your health.

DOI: https://doi.org/10.1111/jdi.12072

Serum adiponectin levels predict the risk of coronary heart disease in Japanese patients with type 2 diabetes

Research Objective
This study aimed to find out if levels of a protein called adiponectin in the blood can predict the risk of coronary heart disease (CHD) in Japanese patients with type 2 diabetes, similar to what has been observed in Caucasian populations.

Methods
Researchers followed 504 Japanese patients with type 2 diabetes for a median of 5.7 years. They used statistical methods (Cox proportional hazard analysis) to assess how baseline serum adiponectin levels related to the risk of developing new or recurrent CHD.

Main Findings
During the study period, 50 participants experienced CHD events. After accounting for other known heart disease risk factors, patients with the highest levels of serum adiponectin had a significantly reduced risk of CHD compared to those with the lowest levels (a 65% lower risk). Doubling the adiponectin level was associated with a 39% lower risk of CHD. This suggests a strong link between higher adiponectin and lower heart disease risk, independent of other factors.

Clinical Significance
High serum adiponectin levels are significantly associated with a lower risk of coronary heart disease in Japanese patients with type 2 diabetes. This confirms that adiponectin is an important predictor for CHD in this population, similar to previous findings in Caucasians.

Key Points for Patients
Adiponectin is a protein that appears to play a protective role against heart disease, especially in people with type 2 diabetes. Higher levels of this protein are linked to a lower risk of developing heart problems. This finding could help doctors identify patients at higher risk and potentially guide future treatments aimed at improving heart health.

DOI: https://doi.org/10.1111/jdi.12078

Weight reduction is associated with improvement of glycemic control in Japanese men, whose hemoglobin A1C is 5.6–6.4%, with visceral fat accumulation, but not without visceral fat accumulation

Research Objective
This study investigated whether weight reduction improves blood sugar control (measured by HbA1c between 5.6% and 6.4%) in Japanese men, specifically looking at how this is affected by whether they have visceral fat accumulation (fat around internal organs).

Methods
Researchers studied 798 Japanese men with HbA1c levels between 5.6% and 6.4%. They divided these men into groups based on their Body Mass Index (BMI) and estimated visceral fat area (eVFA). The study then looked at the relationship between changes in BMI and changes in HbA1c over one year.

Main Findings
Weight reduction (decrease in BMI) was associated with improved HbA1c levels, but this link was much stronger and more significant in men who had accumulated visceral fat (eVFA ≥100 cm²), regardless of their overall BMI. For men without significant visceral fat accumulation (eVFA <100 cm²), there was no clear association between weight change and HbA1c improvement.

Clinical Significance
These results suggest that assessing visceral fat levels, rather than just BMI, might be more important for identifying individuals who would benefit most from lifestyle changes aimed at weight reduction to improve or prevent diabetes.

Key Points for Patients
If you're looking to improve your blood sugar control or prevent diabetes, especially if your HbA1c is in the pre-diabetes range (5.6-6.4%), losing weight can be very effective. This study highlights that it's particularly beneficial if you have a lot of fat around your internal organs (visceral fat). Knowing your visceral fat levels might help you and your doctor decide on the best weight management strategy.

DOI: https://doi.org/10.1111/jdi.12084

Morphometric features of corneal epithelial basal cells, and their relationship with corneal nerve pathology and clinical factors in patients with type 2 diabetes

Research Objective
This study aimed to examine changes in the cells of the cornea (the clear, outer layer of the eye) in patients with type 2 diabetes and to see how these changes relate to nerve damage in the cornea and other health factors.

Methods
Researchers used a special microscope called a corneal confocal microscope to visualize the cells at the base of the corneal epithelium and the corneal nerve fibers in 75 patients with type 2 diabetes and 42 healthy individuals. They measured various features of these cells, such as their density, size, variability in size, and the space between them.

Main Findings
Patients with type 2 diabetes showed several changes in their corneal cells compared to healthy controls: decreased cell density, smaller cell area, greater variability in cell area, and wider spaces between cells. These cellular changes were linked to how long a person had diabetes, the presence of 'beading' (a sign of damage) in corneal nerve fibers, and factors related to blood clotting (like fibrinogen levels).

Clinical Significance
Type 2 diabetes induces specific structural changes in corneal epithelial basal cells. These changes appear to be related to the duration of diabetes, nerve damage in the cornea, and the blood's ability to clot. This research could offer new ways to understand and potentially detect diabetes complications affecting the eyes.

Key Points for Patients
Diabetes can affect many parts of your body, including your eyes, down to the cellular level. This study shows that the clear front layer of your eye (the cornea) undergoes subtle changes in people with type 2 diabetes. These changes are linked to how long you've had diabetes and signs of nerve damage in the eye. Understanding these changes might one day help doctors identify diabetes-related eye problems earlier.

DOI: https://doi.org/10.1111/jdi.12083

Increasing achievement of the target goals for glycemic, blood pressure and lipid control for adults with diagnosed diabetes in Korea

Research Objective
This study aimed to examine the trends in the prevalence (how common it is), treatment, and control of diagnosed diabetes among Korean adults from 1998 to 2010.

Methods
Researchers analyzed data from the Korean National Health and Nutrition Examination Survey (KNHANES) conducted between 1998 and 2010. They looked at how many adults had diagnosed diabetes and what percentage achieved target goals for HbA1c (less than 7.0%), blood pressure (less than 130/80 mmHg), and LDL cholesterol (less than 100 mg/dL), according to American Diabetes Association guidelines.

Main Findings
The prevalence of diagnosed diabetes in Korea significantly increased from 3.2% in 1998 to 6.4% in 2010. During this period, the proportion of patients meeting blood pressure and LDL cholesterol targets also significantly increased. However, the percentage of patients achieving their glycemic (blood sugar) goals did not significantly increase. While the number of individuals meeting all three targets (blood sugar, blood pressure, and cholesterol) improved, it still remained low (from 2.7% in 2005 to 8.7% in 2010).

Clinical Significance
While the prevalence of diagnosed diabetes in Korea has increased, significant progress has been made in controlling blood pressure and cholesterol levels. However, glycemic control remains a challenge, and there is still much room for improvement in achieving comprehensive management goals for people with diabetes.

Key Points for Patients
More and more people are being diagnosed with diabetes. While doctors and patients are getting better at controlling blood pressure and cholesterol, maintaining ideal blood sugar levels (HbA1c) remains a tough goal for many. This highlights the importance of working closely with your healthcare team to manage all aspects of your diabetes care, as meeting all goals is crucial for long-term health.

DOI: https://doi.org/10.1111/jdi.12077

Advances in Diabetes Care: Upgrading Insulin Pump Technology and Exploring New Therapies for Kidney Protection

Journal of Diabetes Investigation: Vol. 17, Issue 4 Summary

This issue highlights key advancements spanning both advanced diabetes technology and foundational pharmacology. Together, these studies emphasize the rapid evolution of modern diabetes management, showing how patient care is being optimized in real-world clinical practice and pointing toward future organ-protective strategies.

• Advanced Diabetes Technology: Real-world evidence demonstrates that upgrading from the MiniMed™ 770G to the 780G hybrid closed-loop system significantly improves blood sugar stability, reduces night-time hypoglycemia, and eases diabetes-related anxiety in adults with Type 1 Diabetes.
• Preventing Complications: Preclinical research shows that Calebin A, a natural compound, targets inflammation and cell damage pathways to protect kidneys from diabetic nephropathy.
• Relevance to Care: These findings highlight the physical and psychological benefits of upgrading medical devices, while offering hope for novel, protective therapies that could shield patients from long-term diabetic complications.

Disclaimer The information presented in this article is provided for informational purposes only. The blog and its author assume no responsibility for the accuracy, safety, completeness, or reliability of the information. Any actions or decisions based on the information in this article are the sole responsibility of the reader.

This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.

Clinical Research & Technology

Effects of switching from MiniMed™ 770G to 780G on continuous glucose monitoring metrics and DTR-QOL scores: An observational study of Japanese people with type 1 diabetes mellitus

Authors: Eri Takagi, Junko Sato, Tatsuhiro Ayame, Shohei Fujikawa, Ryoki Mori, Haruna Yasuda, Azusa Ozaki, Haruki Nagashima, Mami Koshibu, Yuya Nishida, Fuki Ikeda, Hirotaka Watada

Research Objective:

To evaluate how switching from the MiniMed™ 770G insulin pump to the newer MiniMed™ 780G system affects blood sugar levels and quality of life (QOL) in Japanese adults with Type 1 Diabetes (T1D) over a one-year period.

Methods:

The researchers retrospectively analyzed continuous glucose monitoring (CGM) data from 36 adult patients over 48 weeks. They evaluated the time spent in the ideal blood sugar range (70–180 mg/dL), as well as high and low blood sugar levels. Additionally, they prospectively measured treatment-related quality of life (DTR-QOL) in 39 patients using standard questionnaires.

Main Findings:

• Time in Range (70-180 mg/dL): Significantly increased from 71.6% to 76.1%.
• High Blood Sugar: Time spent above 180 mg/dL decreased from 25.2% to 21.0%.
• Hypoglycemia: While overall low blood sugar rates remained stable, nighttime low blood sugars (nocturnal hypoglycemia) dropped significantly from 4.9% to 2.7%.
• A1C Levels: Average HbA1c improved from 7.2% to 7.0%.
• Quality of Life: Patients reported significantly lower levels of diabetes-related anxiety and higher overall satisfaction with their treatment.

Clinical Significance:

This study provides the first one-year, real-world evidence of MiniMed™ 780G use in Japan. It demonstrates that the newer system's automated features translate directly to more stable blood sugars and happier, less anxious lives for patients.

Key Points for Patients & Families Upgrading from the MiniMed™ 770G to the 780G system can help keep your blood sugar in the healthy range longer and lower your HbA1c. Most notably, the 780G reduces the risk of dangerous blood sugar drops overnight and significantly eases daily diabetes stress and anxiety.

DOI: https://doi.org/10.1111/jdi.70257 (Read the original article)

Basic & Animal Research

Calebin A mitigates oxidative stress and inflammation in diabetic nephropathy via Nrf2/HO‐1 and NF‐κB signaling pathways

Authors: Reyhane Ghayour Vatanparast, Mahdieh Aliyari, Mahla Palizkaran Yazdi, Soodeh Alidadi, Mohammad Reza Sokhanvar, Sercan Karav, Prashant Kesharwani, Hossein Hosseini, Amirhossein Sahebkar

Research Objective:

To study the potential kidney-protecting (nephroprotective) properties and the underlying biological mechanisms of Calebin A, a natural compound related to turmeric, in treating diabetic nephropathy (kidney disease).

Methods:

Diabetic nephropathy was induced in mice. The mice were then treated with Calebin A, curcumin, or metformin for six weeks. Researchers examined their blood sugar, kidney function, signs of cell stress, inflammation, and physical scarring (fibrosis) in the kidney tissues.

Main Findings:

• Kidney Protection: Calebin A treatment significantly improved blood sugar control and overall kidney performance.
• Pathology Improvement: Tissue samples showed less physical damage and scarring in the kidneys of treated mice.
• Cellular Mechanism: It successfully reduced harmful cell stress by boosting the body's natural antioxidant defense (Nrf2 pathway) and reduced swelling by blocking the inflammatory pathway (NF-κB pathway).

Clinical Significance:

These findings show that Calebin A holds strong potential as a multi-target natural therapy to protect kidneys from high blood sugar damage. However, because this was an animal study, further clinical trials are necessary to confirm if these protective effects work similarly in humans.

Key Points for Patients & Families Diabetic kidney disease is a serious complication caused by long-term high blood sugar. This promising laboratory study reveals that Calebin A (a natural compound) could serve as a future therapeutic option to help protect kidneys from swelling, scarring, and permanent damage.

DOI: https://doi.org/10.1111/jdi.70267 (Read the original article)

Diabetes Care Insights: COVID-19 Impact, Elderly Management, Novel Therapies, and Men's Health in Focus

Issue Summary (JDI Vol.13, Issue12)

This issue of the Journal of Diabetes Investigation presents a diverse collection of research, shedding light on critical aspects of diabetes care, from the far-reaching impact of global events to advancements in therapeutic strategies and overlooked patient needs.

A notable theme explores the metabolic consequences of the COVID-19 pandemic. One study specifically examines the year-long effects of voluntary restrictions in Japan on individuals with glucose intolerance, revealing significant increases in body weight and fat mass, along with decreased skeletal muscle, highlighting the need for continued lifestyle support during public health crises.

Another key area of focus is the evolving landscape of diabetes management in elderly patients, particularly those with cognitive impairments. Research from memory clinics in Japan indicates a shift in glycemic targets to avoid hypoglycemia, yet also signals an increase in average HbA1c levels, underscoring the complexities of individualized care for this vulnerable population.

The issue also provides exciting insights into potential future treatments with a review on novel GLP-1R/GIPR/GCGR triagonists, which promise a multi-faceted approach to tackle obesity and type 2 diabetes by promoting both weight loss and improved glycemic control.

Furthermore, critical risk factors for hypoglycemia unawareness and severe hypoglycemia in type 1 diabetes patients are meticulously analyzed, emphasizing the importance of blood glucose variability in identifying high-risk individuals. Finally, a significant review addresses the often-neglected topic of men's sexual health in Asia for those with prediabetes and diabetes, calling for improved awareness and holistic management strategies.

Collectively, these studies highlight the ongoing challenges and innovations in diabetes care, emphasizing the importance of personalized approaches, lifestyle interventions, and comprehensive patient-provider communication to improve outcomes and quality of life for individuals living with diabetes.

Disclaimer

The information presented in this article is provided for informational purposes only. The blog and its author assume no responsibility for the accuracy, safety, completeness, or reliability of the information. Any actions or decisions based on the information in this article are the sole responsibility of the reader.

This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.

Year-long effects of COVID-19 restrictions on glycemic control and body composition in patients with glucose intolerance in Japan: A single-center retrospective study

Research Objective This study aimed to evaluate how the voluntary COVID-19 restrictions in Japan affected blood sugar control and body composition (like body fat and muscle) in patients with glucose intolerance over a year.

Methods Researchers conducted a retrospective study at a single center, looking back at data from 415 outpatients with glucose intolerance. They specifically included patients who had long-term body composition data, received dietary follow-up from nutritionists, and had their HbA1c (a measure of average blood sugar over 2-3 months) levels recorded both before and after the declaration of a state of emergency due to COVID-19.

Main Findings Overall, the study found no significant changes in HbA1c levels. However, patients experienced significant increases in body weight and fat mass, and a significant decrease in skeletal muscle mass. Changes in HbA1c were directly linked to changes in body weight and fat mass. In particular, patients whose HbA1c increased by 0.3% or more showed larger increases in body weight and fat mass. Lifestyle changes, such as increased snacking, were associated with worse blood sugar control.

Clinical Significance Even voluntary COVID-19 restrictions in Japan led to negative metabolic consequences for people with glucose intolerance, including increased body weight, body fat, and reduced muscle. These changes can worsen blood sugar control. Healthcare providers need to be aware of these risks and intervene to help patients maintain healthy lifestyles during similar situations.

Key Points for Patients During times of restriction or changes in routine, it's crucial to be mindful of your eating habits and physical activity. Increased snacking can negatively impact your blood sugar. Try to maintain a balanced diet and regular exercise to manage your weight, body fat, and muscle mass, as these factors directly influence your glucose control.

DOI: https://doi.org/10.1111/jdi.13893

Time trends (2012–2020) in glycated hemoglobin and adherence to the glycemic targets recommended for elderly patients by the Japan Diabetes Society/Japan Geriatrics Society Joint Committee among memory clinic patients with diabetes mellitus

Research Objective This study aimed to examine how average blood sugar levels (HbA1c) and the quality of blood sugar control changed over time (from 2012 to 2020) in elderly diabetes patients attending memory clinics, particularly in relation to new glycemic targets set for older individuals.

Methods This was a cross-sectional study involving 1,436 diabetes patients aged 65 years or older. Patients were divided into three groups based on their cognitive function (memory and thinking abilities) and daily living activities. Researchers analyzed trends in HbA1c levels, how well blood sugar was controlled (optimally, poorly, or excessively), and the use of medications that could cause severe low blood sugar, adjusting for other influencing factors.

Main Findings Between 2012 and 2020, the average HbA1c levels and the proportion of patients with poorly controlled blood sugar increased. Conversely, the proportion of patients with excessively low blood sugar control and those receiving drugs associated with severe hypoglycemia decreased. This suggests a shift in treatment strategies for older patients to avoid low blood sugar.

Clinical Significance The findings reflect a recent trend in diabetes management for older adults, focusing on preventing dangerous low blood sugar (hypoglycemia). However, the increase in HbA1c and poor control highlights a potential trade-off. It suggests a need for more flexible and personalized blood sugar targets for elderly patients, taking into account their overall health, including other health conditions and risks of complications from high blood sugar.

Key Points for Patients If you are an older adult with diabetes, especially if you have memory concerns, your healthcare team aims to balance keeping your blood sugar in a healthy range with preventing dangerously low blood sugar. It's important to have an open discussion with your doctor about your individual blood sugar goals, considering your overall health and lifestyle, to ensure a treatment plan that works best for you.

DOI: https://doi.org/10.1111/jdi.13897

Potential of a glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes

Research Objective This article explores the potential of new medications called triagonists (like SAR441255) that target three different receptors – GLP-1R, GIPR, and GCGR – for treating obesity and type 2 diabetes.

Methods This is a review article describing the mechanism and observed effects of these triagonists. It discusses how these compounds bind to and activate specific receptors (GLP-1R, GIPR, and GCGR) in the body to produce beneficial effects, based on studies in animal models of obesity and type 2 diabetes.

Main Findings The review highlights that these triagonists, by interacting with GLP-1R, GIPR, and GCGR, can lead to both significant weight loss and improved blood sugar control in animal models of type 2 diabetes and obesity.

Clinical Significance These novel multi-targeted drugs represent a promising advancement in treating obesity and type 2 diabetes. By activating three key pathways involved in metabolism, they could offer more comprehensive and effective solutions for weight management and blood sugar regulation compared to existing treatments.

Key Points for Patients Researchers are developing exciting new medications that could help people with type 2 diabetes and obesity manage both their weight and blood sugar more effectively. These drugs work by targeting several important natural pathways in the body simultaneously, offering a potentially powerful new approach to treatment.

DOI: https://doi.org/10.1111/jdi.13896

Factors associated with hypoglycemia unawareness and severe hypoglycemia in type 1 diabetes mellitus patients

Research Objective This study aimed to identify the factors that increase the risk of hypoglycemia unawareness (not feeling symptoms of low blood sugar) and severe hypoglycemia (very low blood sugar requiring help from others) in Japanese patients with type 1 diabetes.

Methods Researchers used a self-administered questionnaire completed by 1,619 patients with type 1 diabetes, gathering information on hypoglycemia events, complications, and treatments. They used statistical analysis (multiple logistic regression) to find factors associated with hypoglycemia unawareness and severe hypoglycemia. The variability of blood glucose levels (how much they fluctuate) was also calculated from blood samples collected over six outpatient visits.

Main Findings The study found that 44.2% of participants experienced hypoglycemia unawareness, and 10.4% had severe hypoglycemia. Patients with hypoglycemia unawareness generally had lower average HbA1c levels. Key factors predicting hypoglycemia unawareness were the specific type of type 1 diabetes, HbA1c level, blood glucose variability, and a history of severe hypoglycemia. For severe hypoglycemia, the most important predictors were blood glucose variability and a history of hypoglycemia unawareness. Patients with high blood glucose variability and low HbA1c levels faced the highest risk for both these adverse events.

Clinical Significance Blood glucose variability (the 'ups and downs' of blood sugar) is a crucial independent predictor for both hypoglycemia unawareness and severe hypoglycemia in type 1 diabetes. Healthcare providers should pay special attention to patients who show high glucose variability, especially if they also have a relatively low HbA1c, as these individuals are at a significantly higher risk. Their treatment plans may need to be carefully reviewed and adjusted.

Key Points for Patients If you have type 1 diabetes, it's important to understand not just your average blood sugar (HbA1c) but also how much your blood sugar levels fluctuate throughout the day. High variability in blood sugar can increase your risk of not feeling when your blood sugar is low (hypoglycemia unawareness) and having severe low blood sugar episodes. Discuss these risks with your doctor, especially if your blood sugar swings a lot or you've had severe low blood sugar in the past, so your treatment plan can be optimized for safety.

DOI: https://doi.org/10.1111/jdi.13886

Gaps in the management of diabetes in Asia: A need for improved awareness and strategies in men's sexual health

Research Objective This review article highlights the prevalence, underlying causes, and challenges in managing male sexual dysfunction in men with prediabetes and diabetes across Asia, emphasizing the need for better awareness and strategies.

Methods This is a comprehensive review discussing the existing scientific literature on the epidemiology (how common it is), pathophysiology (how it develops), and current management of common male sexual dysfunctions – hypogonadism (low testosterone), erectile dysfunction (ED), and premature ejaculation (PE) – in men with prediabetes and both type 1 and type 2 diabetes. It specifically identifies gaps in care within Asian populations.

Main Findings Sexual dysfunction is very common in men with prediabetes and diabetes globally and is often an early indicator of cardiovascular disease. It significantly affects a man's physical, mental, and social well-being. Despite its importance, discussing sexual health openly remains a challenge in Asian clinical practice due to barriers from both patients and healthcare providers.

Clinical Significance Addressing sexual health is a vital but often overlooked component of comprehensive diabetes management. Given its prevalence and impact on quality of life and cardiovascular risk, healthcare providers need to adopt a holistic approach, improving communication and incorporating assessment and management of sexual dysfunction into routine clinical care for men with diabetes.

Key Points for Patients If you are a man with prediabetes or diabetes and are experiencing sexual health issues like erectile dysfunction, low libido, or premature ejaculation, please know that these are common and can be an important indicator of your overall health, including heart health. It is essential to discuss these concerns with your doctor, even if it feels uncomfortable, as there are effective treatments and support available. Open communication with your healthcare provider is key to addressing these issues and improving your quality of life.

DOI: https://doi.org/10.1111/jdi.13903

Advances in Diabetes Care: Key Insights from the Journal of Diabetes Investigation (Vol. 13, Issue 3)

Journal of Diabetes Investigation: Vol. 13, Issue 3 Review

In this issue of the Journal of Diabetes Investigation, clinical researchers explore several critical facets of diabetes management, complications, and early risk assessment. Key investigations focus on the metabolic impacts of clinical dropout, the synergistic dangers of combined vision and hearing impairments on cardiovascular outcomes, and nuanced screening metrics for prediabetes.

Key Takeaways for Patients and Families: Continuous clinical oversight remains the cornerstone of safe diabetes management. Gaps in care can trigger severe blood sugar spikes, particularly for patients prescribed insulin or sulfonylureas. Furthermore, sensory health assessments (vision and hearing) are shown to be essential indicators of overall cardiovascular risk, and early-stage screening tools like the Visceral Adiposity Index (VAI) or combined ankle-brachial index sweat tests are making preventative interventions more precise than ever.

Disclaimer
The information presented in this article is provided for informational purposes only. The blog and its author assume no responsibility for the accuracy, safety, completeness, or reliability of the information. Any actions or decisions based on the information in this article are the sole responsibility of the reader.

This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.

Continuity of Care

Glycemic Deterioration After Dropping Out of Type 2 Diabetes Care

Research Objective: To identify factors associated with worsening blood sugar control (HbA1c) when patients with type 2 diabetes temporarily stop receiving clinical care.

Methods: A retrospective cohort study analyzed medical claims and health checkup data of 1,125 Japanese workers with type 2 diabetes who had paused their clinical care for at least 4 months after receiving continuous care for over 1.5 years.

Main Findings: Following an average dropout period of 9.3 months, the average HbA1c level rose from 6.8% to 7.6%. Patients who were taking insulin or sulfonylureas before their dropout experienced a severe increase in HbA1c of approximately 2% or more, even if their blood sugar had been well-controlled prior to the gap in treatment. Patients not on medication experienced far smaller increases (+0.5%).

Clinical Significance: A temporary halt in care poses a high risk for rapid metabolic deterioration, especially for those dependent on advanced glucose-lowering drugs.

What this means for you: Skipping your diabetes clinic appointments is dangerous, particularly if you are prescribed insulin or sulfonylureas. Even if your blood sugar feels controlled, stopping therapy without supervision can lead to rapid and severe health setbacks.

DOI: https://doi.org/10.1111/jdi.13681
Read the original article

Sensory Complications & Cardiovascular Risk

Impact of Vision and Hearing Impairments on Cardiovascular Health in Type 2 Diabetes

Research Objective: To examine how vision loss, hearing loss, or a combination of both relates to cardiovascular disease risk and overall mortality in individuals with type 2 diabetes.

Methods: A large nationwide cohort study evaluated 771,128 patients with type 2 diabetes in South Korea, comparing rates of myocardial infarction (MI), stroke, and mortality among those with and without sensory impairments.

Main Findings: Patients with sensory deficits exhibited elevated risk profiles. Those suffering from both vision and hearing impairments had the highest vulnerability, presenting an adjusted hazard ratio of 1.362 for MI and 1.591 for mortality. Vision loss alone was linked to a higher risk of adverse cardiovascular outcomes and mortality than hearing loss alone.

Clinical Significance: Vision and hearing impairments serve as potent independent and synergistic markers for severe cardiovascular events and overall mortality in diabetes patients.

What this means for you: Routine eye and ear examinations do more than protect your senses; they are vital windows into your heart and vascular system. If you notice deterioration in your sight or hearing, discuss cardiovascular screening with your doctor.

DOI: https://doi.org/10.1111/jdi.13689
Read the original article

Early Diagnostics

Fasting Plasma Glucose of 90–99 mg/dL and Type 2 Diabetes Risk

Research Objective: To clarify whether a fasting blood sugar level between 90 and 99 mg/dL—traditionally considered "normal"—increases the risk of developing type 2 diabetes.

Methods: This long-term retrospective cohort study tracked 37,148 Japanese individuals with normal baseline blood glucose over a 10-year period (2008 to 2018).

Main Findings: Within the 90–99 mg/dL range, the risk of developing type 2 diabetes rose by 9% for every 1 mg/dL increase. Compared to individuals with fasting glucose ≤89 mg/dL, those at 98–99 mg/dL had over a 3.4-fold higher risk of developing diabetes, with the hazard ratio remaining highly pronounced among individuals with obesity.

Clinical Significance: The risk of progressing to type 2 diabetes increases linearly and significantly even within what is widely considered a normal fasting blood sugar range.

What this means for you: Having a fasting blood sugar level in the high 90s is not entirely risk-free. It serves as an early warning, particularly if you are carrying extra weight, indicating that proactive lifestyle modifications could prevent diabetes.

DOI: https://doi.org/10.1111/jdi.13692
Read the original article

Retinopathy Mechanisms

LncRNA ATP2B1-AS1 Regulates Blood Vessel Leakage in Diabetic Retinopathy

Research Objective: To investigate how the long non-coding RNA (lncRNA) ATP2B1-AS1 influences biological abnormalities in retinal cells exposed to high sugar levels.

Methods: A laboratory-based molecular study evaluating human retinal endothelial cells (HRECs) under high-glucose conditions mimicking diabetes.

Main Findings: ATP2B1-AS1 was found to be downregulated in diabetic retinopathy. Artificially restoring (overexpressing) its levels significantly reduced cell growth, cellular migration, unwanted new blood vessel growth (angiogenesis), and vessel leakiness (permeability) induced by high glucose. This protective effect occurred because ATP2B1-AS1 acts as a "sponge" for miR-4729, which in turn regulates the IQGAP2 gene.

Clinical Significance: This study maps out a new genetic protective pathway in retinal cells, opening the door for future targeted genetic therapies to prevent vision loss.

What this means for you: Researchers are pinpointing the exact genetic mechanisms behind eye damage caused by diabetes. Discoveries like this help pave the way for highly targeted medications in the future to stop retinopathy before it damages sight.

DOI: https://doi.org/10.1111/jdi.13740
Read the original article

Prediabetes Biomarkers

Visceral Adiposity Index as an Indicator for Prediabetes Risk

Research Objective: To synthesize existing observational evidence to clarify whether the Visceral Adiposity Index (VAI)—a combined measure of fat distribution and lipid levels—is associated with prediabetes risk.

Methods: A systematic meta-analysis combining data from 10 observational studies involving a total of 112,603 participants.

Main Findings: Higher VAI scores were significantly associated with an elevated risk of prediabetes. The overall combined odds ratio of VAI for prediabetes was 1.68, although there was notable heterogeneity and publication bias across the studied pools.

Clinical Significance: VAI serves as a useful lipid-and-body-measurement index that clinicians can use to flag individuals who are highly likely to develop prediabetes.

What this means for you: Evaluating your risk for prediabetes involves more than just a scale. By looking at a combined picture of your body fat distribution and cholesterol panel, doctors can better understand your risk and help you take preventative action early.

DOI: https://doi.org/10.1111/jdi.13685
Read the original article

Insulin & Therapy Innovation

Simplified Combination Therapy vs. Multiple Daily Injections in Japanese Type 2 Patients

Research Objective: To compare the clinical efficacy, safety, and blood sugar stability of a simplified once-daily combined injection (iGlarLixi + insulin glulisine) against a traditional intensive multiple daily injection (MDI) regimen.

Methods: A randomized trial involving 40 hospitalized Japanese type 2 diabetes patients, monitored with intermittent continuous glucose monitoring (iCGM) to adjust doses and track glucose metrics.

Main Findings: Both therapies offered comparable "time in range" (healthy blood sugar window). However, the combined iGlarLixi + glulisine therapy significantly reduced time spent in hypoglycemia (low blood sugar), required a shorter medication adjustment (titration) period, and simplified the overall treatment process.

Clinical Significance: Transitioning to a simplified combined therapy maintains strong blood sugar control while offering a safer profile with fewer daily injections and lower hypoglycemia risks.

What this means for you: Managing diabetes does not always have to mean taking numerous complex shots. Combined formulas can provide equivalent glycemic control with fewer needle sticks and a lower danger of sudden, scary low blood sugar events.

DOI: https://doi.org/10.1111/jdi.13677
Read the original article

Therapeutic Molecules

Effects of EPA on Selenoprotein P and Organ-Specific Insulin Sensitivity

Research Objective: To investigate if taking eicosapentaenoic acid (EPA)—a polyunsaturated fatty acid—reduces circulating levels of Selenoprotein P (SeP, a protein that induces insulin resistance) and improves organ-specific insulin response in humans.

Methods: 20 participants with dyslipidemia and type 2 diabetes were randomized to receive 900 mg of EPA twice daily or control for 12 weeks. Detailed insulin sensitivity tests (hyperinsulinemic-euglycemic clamp with stable isotope tracer) were conducted.

Main Findings: Overall circulating SeP levels did not decrease in either group. However, EPA treatment significantly improved insulin sensitivity in fat (adipose) tissue. In individual correlations, higher EPA levels were positively associated with improved hepatic (liver) insulin sensitivity, though surprisingly showing a negative association in skeletal muscle.

Clinical Significance: EPA's ability to bolster insulin response in the liver and fat tissues appears to work through complex, tissue-specific mechanisms independent of circulating SeP levels.

What this means for you: High-quality EPA (often derived from fish oil) can help improve how your body fat and liver respond to insulin. However, its metabolic actions are complex, so it should be used in coordination with your standard medical therapies.

DOI: https://doi.org/10.1111/jdi.13697
Read the original article

Circulatory Screening

Combining Ankle-Brachial Index and Foot Sweat Conductance for Early Leg Artery Disease

Research Objective: To evaluate the early diagnostic value of combining the ankle-brachial index (ABI) with feet electrochemical skin conductance (FESC, measuring sweat response) to detect peripheral artery disease (PAD) in Chinese type 2 diabetes patients.

Methods: Evaluated 183 type 2 diabetes patients who were classified into three groups: uncomplicated diabetes, patients with nerve damage (neuropathy), and patients with established PAD.

Main Findings: FESC (measured via a rapid Sudoscan test) was identified as an independent risk factor for developing PAD. Combining the standard ankle-brachial blood pressure index with FESC produced excellent diagnostic results, achieving an accuracy area under the curve (AUC) of 0.907, with 91.4% specificity and 75% sensitivity.

Clinical Significance: Combining vascular (ABI) and sweat gland nerve (FESC) screenings provides an accurate, non-invasive method for detecting diabetes-related leg artery blockages at a very early stage.

What this means for you: Simple, non-invasive skin tests on your feet combined with blood pressure checks on your limbs can detect early signs of poor circulation. Catching these problems early is the key to preventing serious diabetic foot ulcers.

DOI: https://doi.org/10.1111/jdi.13687
Read the original article

Advancing Diabetes Care: Hospital Digital Dashboards, Nerve Regeneration, and Early Support Strategies

Journal of Diabetes Investigation: Vol. 12, Issue 9 Review

This month's issue highlights powerful clinical breakthroughs and practical insights across the spectrum of diabetes care. Key themes include how digital health and remote monitoring dashboards can drastically improve hospital stay durations, the direct nerve-healing benefits of intensive blood sugar control, and how lifestyle containment measures during the pandemic affected younger and older populations in different ways.

Additionally, researchers explore critical safety warnings regarding SGLT2 inhibitor use in Type 1 diabetes, the profound value of immediate nutritional and eye exams in preventing treatment dropouts, and the underlying commonalities between Type 1 and Type 2 diabetes cell failures.

Disclaimer The information presented in this article is provided for informational purposes only. The blog and its author assume no responsibility for the accuracy, safety, completeness, or reliability of the information. Any actions or decisions based on the information in this article are the sole responsibility of the reader.

This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.

Digital Health & Remote Monitoring

Electronic Dashboard-Based Remote Glycemic Management Program Reduces Length of Stay and Readmission Rate Among Hospitalized Adults

Authors: Yi‐Jing Sheen, Chien‐Chung Huang, Shih‐Che Huang, Ching‐Heng Lin, I‐Te Lee, Wayne H‐H Sheu

Research Objective: To evaluate the clinical impact of a 4-year, hospital-wide remote blood glucose monitoring dashboard on the length of hospital stay (LOS) and 30-day readmission rates for hospitalized adult patients.

Methods: A retrospective study evaluating 106,528 hospitalized patients who received glucose monitoring. Patients were divided into four glycemic categories ranging from high variability, hypoglycemia, hyperglycemia, to relatively stable control. Researchers tracked change trends using joinpoint regression from 2016 to 2019.

Main Findings: Implementing the dashboard led to a significant shift from poor blood sugar control categories to the stable group. There was an 11.4% reduction in length of hospital stay and a drop in 30-day readmissions (from 29.9% to 29.3%), primarily driven by patients achieving stable control.

Clinical Significance: Utilizing structured digital remote management tools across an entire hospital system optimizes patient recovery times, reduces the risk of readmission, and decreases associated medical costs.

Key Points for Patients: When hospitals use advanced digital dashboards to closely monitor and manage blood sugar levels remotely, patients recover faster, spend less time in hospital beds, and are less likely to be readmitted shortly after discharge.

DOI: https://doi.org/10.1111/jdi.13500

COVID-19 & Lifestyle Impacts

Lifestyle Changes as a Result of COVID-19 Containment Measures: Bodyweight and Glycemic Control in Patients with Diabetes in the Japanese Declaration of a State of Emergency

Authors: Nagaaki Tanaka, Yoshiyuki Hamamoto, Yuri Kurotobi, Yuji Yamasaki, Susumu Nakatani, Miho Matsubara, Takuya Haraguchi, Yuko Yamaguchi, Kiyohiro Izumi, Yuki Fujita, Hitoshi Kuwata, Takanori Hyo, Yuichiro Yamada, Takeshi Kurose, Yutaka Seino

Research Objective: To clarify how lifestyle changes during the Japanese COVID-19 state of emergency affected metabolic status, body weight, and HbA1c levels in patients with diabetes.

Methods: A single-center, cross-sectional observational study using a self-reported questionnaire from 463 patients to record active habits before and after containment measures. The analysis was stratified by age (under 65 versus 65 and older).

Main Findings: Shifts in HbA1c levels directly correlated with body weight changes. For patients under 65, increased snacking significantly elevated body weight and HbA1c. Conversely, for patients aged 65 and older, weight gain was primarily associated with reduced walking activity.

Clinical Significance: Public health containment measures impact diabetes management in age-dependent ways, requiring customized guidance (snacking management for younger adults and mobility-maintenance programs for seniors).

Key Points for Patients: Major disruptions to daily routines, like pandemic lockdowns, affect our health differently depending on our age. Younger individuals may need to watch mid-day snacking, whereas older adults should focus on maintaining daily physical activities like walking.

DOI: https://doi.org/10.1111/jdi.13526

Pathophysiology & Disease Mechanisms

β-Cell Failure in Diabetes: Common Susceptibility and Mechanisms Shared Between Type 1 and Type 2 Diabetes

Authors: Hiroshi Ikegami, Naru Babaya, Shinsuke Noso

Research Objective: To review shared genetic susceptibilities and common biological pathways of pancreatic beta-cell (insulin-producing cell) failure across both Type 1 and Type 2 diabetes subtypes.

Methods: A comprehensive review of recent literature examining molecular mechanisms and genetic markers involved in diabetic beta-cell degradation.

Main Findings: Despite having distinct starting causes and immune system profiles, Type 1 and Type 2 diabetes share key downstream genetic susceptibilities and molecular pathways that lead to cellular stress and eventual beta-cell death.

Clinical Significance: Pinpointing these universal destructive mechanisms helps researchers design overarching therapies capable of preserving insulin secretion regardless of the patient's specific diabetes subtype.

Key Points for Patients: Although Type 1 and Type 2 diabetes are different conditions, they share a "common enemy" in how their insulin-producing cells fail. Scientists are using these shared biological pathways to research new treatments that could help individuals with either type of diabetes.

DOI: https://doi.org/10.1111/jdi.13576

Animal Physiology Study

Glucokinase is Required for High-Starch Diet-Induced β-Cell Mass Expansion in Mice

Authors: Kazuhisa Tsuchida, Akinobu Nakamura, Hideaki Miyoshi, Kelaier Yang, Yuki Yamauchi, Shinichiro Kawata, Kazuno Omori, Kiyohiko Takahashi, Naoyuki Kitao, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, Yusuke Seino, Yasuo Terauchi, Tatsuya Atsumi

Research Objective: To determine if glucokinase—a key enzyme in glucose metabolism—is necessary for the pancreas to expand its beta-cell mass when exposed to a high-starch diet (HSTD).

Methods: Eight-week-old male wild-type and glucokinase-heterozygous (Gck+/-) mice were fed either a high-starch diet or a control diet, followed by physical and microscopic evaluations of pancreatic tissues.

Main Findings: A high-starch diet naturally triggers an expansion of beta-cell mass and increased insulin secretion in normal wild-type mice, but this crucial protective adaptation is disrupted or impaired in mice lacking a fully functional glucokinase enzyme.

Clinical Significance: This study highlights the essential role of glucokinase in helping the pancreas adapt to carbohydrate-heavy diets, further elucidating how dietary elements interact with genetics.

Key Points for Patients: Laboratory studies show that our bodies rely on specific enzymes (like glucokinase) to help the pancreas safely handle and adapt to high-carbohydrate or high-starch foods. If these enzymes do not function properly, the body may struggle to produce the extra insulin it needs.

DOI: https://doi.org/10.1111/jdi.13532

Drug Safety & Therapeutics

On-Label Use of Sodium-Glucose Cotransporter 2 Inhibitors Might Increase the Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes

Authors: Takeshi Horii, Yoichi Oikawa, Koichiro Atsuda, Akira Shimada

Research Objective: To investigate the real-world risk and timeline of diabetic ketoacidosis (DKA) in patients with Type 1 diabetes who are treated with SGLT2 inhibitors alongside insulin.

Methods: A retrospective, observational cohort study using a major Japanese clinical database. Out of 11,475 adult Type 1 diabetes patients, 1,898 were taking prescribed SGLT2 inhibitors. Incidence rates and hazard ratios of DKA were calculated using Cox multivariate regression.

Main Findings: Patients taking SGLT2 inhibitors experienced a significantly higher rate of DKA compared to non-users (7.3% vs. non-users; Hazard Ratio: 1.66). The average time to DKA onset was approximately 30.6 days after starting the drug, regardless of age, sex, or BMI. Interestingly, patients using continuous subcutaneous insulin pumps did not show an elevated risk, though the sample size was small.

Clinical Significance: Clinicians and Type 1 diabetes patients must be highly vigilant regarding DKA risks when initiating SGLT2 inhibitors, particularly during the critical first month of therapy.

Key Points for Patients: While SGLT2 inhibitors can offer benefits, if you have Type 1 diabetes, starting this medication carries an increased risk of a severe, life-threatening condition called diabetic ketoacidosis (DKA). This risk is highest during the first 30 days, making close monitoring and direct contact with your care team essential.

DOI: https://doi.org/10.1111/jdi.13506

Complications & Nerve Regeneration

Painful Diabetic Neuropathy is Associated with Increased Nerve Regeneration in Patients with Type 2 Diabetes Undergoing Intensive Glycemic Control

Authors: Georgios Ponirakis, Muhammad A Abdul‐Ghani, Amin Jayyousi, Mahmoud A Zirie, Murtaza Qazi, Hamad Almuhannadi, Ioannis N Petropoulos, Adnan Khan, Hoda Gad, Osama Migahid, Ayman Megahed, Salma Al‐Mohannadi, Fatema AlMarri, Fatima Al‐Khayat, Ziyad Mahfoud, Hanadi Al Hamad, Marwan Ramadan, Ralph DeFronzo, Rayaz A Malik

Research Objective: To discover if the presence of painful diabetic nerve damage (neuropathy) impacts the physical regeneration of microscopic corneal (eye) nerves in Type 2 diabetes patients undergoing intensive blood sugar control.

Methods: An exploratory 1-year study evaluating participants with and without painful neuropathy using corneal confocal microscopy (to map small nerve fibers in the eye), skin conductance tests, and pain questionnaires. Patients received active therapies (exenatide + pioglitazone or intensive basal-bolus insulin).

Main Findings: Following intensive glycemic control and a significant drop in HbA1c, patients suffering from painful neuropathy showed a remarkable physical increase in corneal nerve fiber density, nerve length, and branching, alongside a notable decrease in their physical pain scores.

Clinical Significance: Active, rigorous blood sugar management doesn't just halt neuropathy; it actively facilitates small nerve fiber repair and yields real-world pain relief for patients.

Key Points for Patients: Committing to strict blood sugar control can actually help your body rebuild damaged small nerves. Over a year, this structural healing was shown to significantly reduce the daily, distressing pain caused by neuropathy.

DOI: https://doi.org/10.1111/jdi.13544

Preventive Medicine & Care Retention

Association Between Nutritional Guidance or Ophthalmological Examination and Discontinuation of Physician Visits in Patients with Newly Diagnosed Diabetes: A Retrospective Cohort Study Using a Nationwide Database

Authors: Akira Okada, Sachiko Ono, Satoko Yamaguchi, Hayato Yamana, Kayo Ikeda Kurakawa, Nobuaki Michihata, Hiroki Matsui, Masaomi Nangaku, Toshimasa Yamauchi, Hideo Yasunaga, Takashi Kadowaki

Research Objective: To investigate if completing guideline-recommended care (such as nutritional counseling or professional eye exams) within the first month of a diabetes diagnosis prevents patients from dropping out of medical follow-ups.

Methods: A retrospective cohort study analyzing 6,508 newly diagnosed diabetes patients from a nationwide Japanese administrative database. Discontinuation of care was defined as going more than 6 months without a clinical visit.

Main Findings: Patients who underwent nutritional counseling or eye exams within their first month had a significantly lower medical dropout rate (17.2%) compared to those who did not receive these services (21.8%), demonstrating a 21% relative reduction in care abandonment.

Clinical Significance: Early engagement through multi-disciplinary care (nutritional support and preventative screening) is a powerful clinical strategy to keep new patients actively enrolled in long-term diabetes management.

Key Points for Patients: Getting a nutritional consultation or an eye exam right after being diagnosed with diabetes does more than protect your eyesight and diet; it helps you build a strong connection with your healthcare team and keeps you from falling out of the medical system.

DOI: https://doi.org/10.1111/jdi.13510

Biomarkers & Screening

Association Between Serum Prostate-Specific Antigen Concentrations and the Risk of Developing Type 2 Diabetes Mellitus in Chinese Men: A Cohort Study

Authors: Shao‐fen Huang, Ying‐lin Yu, Yun‐feng Cui, Yan‐mei Lou, Min‐qi Liao, Chang‐yi Wang, Shan Xu, Hong‐en Chen, Xu‐ping Gao, Shu‐hong Dai, Xiao‐lin Peng, Dan Zhao, Li Wang, Zhao Ping, Fang‐fang Zeng

Research Objective: To explore the long-term relationship between blood levels of prostate-specific antigen (PSA) and the risk of developing Type 2 diabetes in men.

Methods: A cohort study following 16,811 non-diabetic Chinese men receiving annual health checkups over a median period of 3.8 years. Multi-variable analyses adjusted for age, weight, and other health variables.

Main Findings: Men with higher baseline levels of PSA in their blood had a significantly lower risk of developing Type 2 diabetes. This protective association was particularly prominent among men who were overweight or obese.

Clinical Significance: PSA levels could potentially serve as a biological marker to help doctors gauge and identify Type 2 diabetes risk in male patients.

Key Points for Patients: In men, especially those who struggle with weight, having a slightly higher (but normal) PSA level was associated with a lower chance of developing Type 2 diabetes. Future studies are working to understand the exact biological link behind this trend.

DOI: https://doi.org/10.1111/jdi.13521

Heart & Nerve Complications

Insulin Resistance is Independently Associated with Cardiovascular Autonomic Neuropathy in Type 2 Diabetes

Authors: Yingshan Liu, Yu Peng, Jing Jin, Yanshan Chen, Chuna Chen, Zhenguo Chen, Haishan Huang, Lingling Xu

Research Objective: To investigate the relationship between insulin resistance severity (measured by HOMA2-IR based on C-peptide) and the development of diabetic cardiovascular autonomic neuropathy (DCAN), a dangerous form of nerve damage affecting the heart.

Methods: A clinical study of 109 patients with Type 2 diabetes. DCAN was diagnosed using Ewing tests (cardiovascular reflex tests). The HOMA2-IR index was used to precisely quantify insulin resistance.

Main Findings: Insulin resistance was significantly higher in patients with cardiovascular nerve damage and worsened as the damage progressed. Patients with a HOMA2-IR score greater than 1.735 were at a very high risk of DCAN, and this score proved to be a highly accurate diagnostic predictor.

Clinical Significance: Severe insulin resistance is a strong independent predictor of cardiac nerve damage, highlighting HOMA2-IR as a valuable, simple screening tool to identify high-risk patients before severe heart complications occur.

Key Points for Patients: When the body's cells resist insulin too strongly, it doesn't just raise blood sugar; it also places the nerves that control your heart rate and blood pressure at risk. A simple blood test calculation can tell your doctor if you are in the high-risk zone, allowing for early, protective treatments.

DOI: https://doi.org/10.1111/jdi.13510